Clinical Trials Logo

Fatty Liver clinical trials

View clinical trials related to Fatty Liver.

Filter by:

NCT ID: NCT01260246 Terminated - Type 2 Diabetes Clinical Trials

Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes

Start date: December 2010
Phase: N/A
Study type: Interventional

This is a randomized, double-blind, placebo-controlled trial evaluating the impact of sitagliptin therapy in patients with concomitant type 2 diabetes and non-alcoholic steatohepatitis (NASH) on improving liver disease based on biopsy results. The effect of sitagliptin on other measures such as hormones modifying insulin release and sensitivity (termed adipocytokines), fat distribution, and biomarkers of cardiovascular risk will also be evaluated.

NCT ID: NCT01244503 Terminated - Metabolic Syndrome Clinical Trials

Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to demonstrate that the ¹³C-Octanoate Breath Test (OBT) can be used as an aid, in conjunction with other clinical information and medical history, for evaluating disease severity and detecting NASH with a high probability.

NCT ID: NCT01167088 Terminated - Clinical trials for Non-alcoholic Fatty Liver Disease

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

MARVEL
Start date: November 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether a new medicine, called mitoquinone, will reduce raised liver enzymes due to NAFLD and to see if it is safe.

NCT ID: NCT00878592 Terminated - Clinical trials for Nonalcoholic Steatohepatitis

Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity

Start date: October 2008
Phase: N/A
Study type: Interventional

This study is to assess value of providing classes about dietary and life style modifications to decrease or prevent weight gain, less occurrence or better control of weight gain associated disorders such as high blood sugar, hypertension, heart or brain vessels problems.Candidates for this study will be those who have got liver transplant within 6 months of their post transplant period.

NCT ID: NCT00855907 Terminated - Clinical trials for Inflammatory Bowel Disease

Fatty Liver in Inflammatory Bowel Disease (IBD) Patients

Start date: March 2009
Phase:
Study type: Observational

Fatty liver is known to be one of the most frequent liver pathologies in IBD patients (35-40%). Despite this fact, there are only few publications that evaluated the prevalence of fatty liver in IBD patients. Moreover, the pathogenesis of this phenomenon in IBD has not been widely investigated. The paradox of lean patients and fatty liver can be explained by high use of steroids, by rapid weight loss, and by the abundance of TNFα cytokine in IBD patients that causes insulin resistance. The aim of the study: To evaluate the frequency of fatty liver in a cohort of IBD patients and to learn its risk factors. Methods: One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will be recruited. Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome. Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.

NCT ID: NCT00845845 Terminated - Hepatic Steatosis Clinical Trials

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The current pilot study assesses the use of magnetic resonance imaging (MRI) to quantify hepatic steatosis. It will provide preliminary data regarding the use of omega-3 fatty acid supplementation (Lovaza) for the treatment of nonalcoholic steatohepatitis (NASH).

NCT ID: NCT00742326 Terminated - HIV Clinical Trials

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

Start date: August 2008
Phase: Phase 4
Study type: Interventional
Read more »
NCT ID: NCT00736385 Terminated - Fatty Liver Clinical Trials

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

NAFLD
Start date: April 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.

NCT ID: NCT00694746 Terminated - Clinical trials for Non-alcoholic Fatty Liver Disease

Study of Fish Oil to Reduce ALT Levels in Adolescents

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis on CT-scan is safe and will result in decreased ALT.

NCT ID: NCT00678587 Terminated - HIV Infection Clinical Trials

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

ELEVATE
Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive procedures. The clinical benefit of eltrombopag will be measured by the proportion of subjects who avoid platelet transfusions, before, during and up to 7 days after undergoing an invasive procedure. In addition, bleeding events will be monitored during this time. The number of transfusions, safety events and medical resource utilisation will be monitored during this time and for up to 30 days after undergoing an invasive procedure to help further evaluate clinical benefit.